Next Breath A.I CyberSecurity Scoring
19/12/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Next Breath in 2026.
No incidents recorded for Next Breath in 2026.
No incidents recorded for Next Breath in 2026.
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.
Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Latest updates, reports, and threat intel affecting the global network.
The hype around artificial intelligence is at an all-time high in the cybersecurity industry. There's hardly a modern security program that doesn't...
It's been over 10 years since a Kohinoor made its appearance on the silver screen in director Vinay Govind's Kohinoor.
On Aug. 6, Tom Artiom Alexandrovich, a bigwig in Israel's cybersecurity apparatus, was arrested in Las Vegas alongside seven other men...
The executive director of the National Technology Security Coalition writes that Plankey is a strong, capable leader who will strengthen...
State Rep. Monique Miller: I am committed to finding a more secure and predictable way to fund the (cybersecurity) grant program.
Get ready for the gripping underwater thriller Last Breath. Learn everything about the film, from cast details to the latest updates.
As we end the first quarter of the 21st century, cybersecurity threats seem more daunting than ever. So what cyber trends, forecasts,...
As we step into 2025, the cybersecurity landscape will continue to change at an unprecedented pace. As a result, we will need to adopt a...
November was a momentous month, as Australia welcomed significant cyber law reform, including the Cyber Security Act 2024.
The Bluetooth Classic Hands-Free Profile HF role in subsys/bluetooth/host/classic/hfp_hf.c does not release the AT command buffers that are still queued on hf->tx_pending when the RFCOMM DLC goes down. hfp_hf_disconnected() only cancelled the work items and cleared hf->acl, and no other code path ever dequeues those buffers, so each one is permanently lost from the fixed hf_pool (CONFIG_BT_MAX_CONN + 1 buffers, i.e. two in the default configuration). The same function also left BT_HFP_HF_FLAG_CONNECTED set, and hfp_hf_create() wiped the object with memset() as soon as hf->acl was NULL, without checking whether hf->work, hf->slc_work or hf->deferred_work was still pending or running. The remote Audio Gateway peer controls the trigger end to end and needs no application involvement: an unsolicited +BCS: 1 response makes bcs_handle() call bt_hfp_hf_select_codec() and queue an AT+BCS buffer, which cannot be transmitted while BT_HFP_HF_FLAG_RX_ONGOING is set, and an immediately following RFCOMM DISC strands that buffer. Repeating the connect / +BCS / disconnect cycle a couple of times empties hf_pool for good. With the pool exhausted, HFP command sending fails permanently, and because hfp_hf_send_cmd() allocates with K_FOREVER (bt_rfcomm_create_pdu() → bt_conn_create_pdu()) from the Bluetooth RX context — where that timeout is not downgraded to K_NO_WAIT — one further +BCS from the peer parks the Bluetooth RX thread inside net_buf_alloc() with no possible waker, halting all HCI event processing until the device is rebooted. Separately, reusing the HF slot while a work handler was still queued or running allowed memset() to wipe live k_work items out from under the system workqueue, corrupting shared kernel workqueue state. Exploitation requires an established HFP session (for SSP devices L2CAP enforces authentication before the RFCOMM channel is reachable) and a build with CONFIG_BT_HFP_HF enabled.
The user-mode syscall verifier z_vrfy_rtio_cqe_get_mempool_buffer() in subsys/rtio/rtio_syscalls.c validated its two output parameters, buff and buff_len, with K_SYSCALL_MEMORY_READ() rather than K_SYSCALL_MEMORY_WRITE(). Both are pure out-parameters: z_impl_rtio_cqe_get_mempool_buffer() stores the mempool buffer address and its length through them. The distinction is enforced by every architecture validator — arch_buffer_validate() on RISC-V PMP explicitly accepts the global __rom_region/__rodata_region for reads only, and the ARM MPU validators accept P_RO_U_RO and P_RW_U_RO regions for reads only — so a read-validated pointer is not necessarily writable by the calling thread. An unprivileged user-mode thread that has been granted access to an RTIO context (rtio_access_grant()) can invoke the rtio_cqe_get_mempool_buffer() syscall with buff/buff_len pointing at memory it may read but not write, and with a completion-queue entry whose flags field it fully controls (only RTIO_CQE_FLAG_MEMPOOL_BUFFER in flags[7:0] is required; flags[19:8] and flags[31:20] supply the block index and count). The kernel then performs a pointer-sized and a 4-byte store through those addresses while running in supervisor mode. Reaching the store requires CONFIG_USERSPACE together with CONFIG_RTIO_SYS_MEM_BLOCKS, the configuration behind RTIO_DEFINE_WITH_MEMPOOL; without the latter the implementation returns -ENOTSUP and writes nothing. Two outcomes follow. If the target lies in a memory-domain partition declared K_MEM_PARTITION_P_RW_U_RO (privileged read-write, user read-only), the kernel-mode store succeeds and deposits partly attacker-chosen values into memory the memory domain had marked read-only for that thread, bypassing the partition's write protection. If the target lies in globally readable but unwritable memory such as .text/.rodata in flash, the store faults in kernel mode; the fault is delivered to z_fatal_error() and the default k_sys_fatal_error_handler() halts or reboots the device, giving an unprivileged thread a reliable full denial of service. The read-permission check does bound the damage: the address must still be readable by the calling thread, so kernel-private memory cannot be targeted and no confidential data is disclosed. The fix replaces both checks with K_SYSCALL_MEMORY_WRITE(), so a thread lacking write permission is terminated by K_OOPS before the implementation runs; the cqe argument correctly remains read-validated.
IBM Storage TS4500 Library 1.1.1.6 through 1.12.0.3 could allow a remote authenticated attacker to gain unauthorized administrative privileges due to a race condition.
The html_to_markdown expansion module in MISP Modules contains a server-side request forgery (SSRF) vulnerability in its is_safe_url() URL validation function. The BLOCKED_RANGES list used to reject unsafe destination addresses was incomplete, omitting several critical IP address ranges. Specifically, the following ranges were not blocked: 0.0.0.0/8 (unspecified, which routes to loopback on Linux), 100.64.0.0/10 (carrier-grade NAT per RFC 6598), ::/128 (IPv6 unspecified), fc00::/7 (IPv6 Unique Local Addresses), and fe80::/10 (IPv6 link-local). The existing list only covered IPv4 loopback (127.0.0.0/8), RFC 1918 private ranges, IPv4 link-local (169.254.0.0/16), and IPv6 loopback (::1/128). An authenticated user with the ability to create or modify MISP attributes that trigger the html_to_markdown expansion module could supply URLs pointing to these unblocked internal address ranges. Because the module fetches the URL server-side to convert HTML content to Markdown, the request is made from the MISP server's network context. This allows an attacker to probe and read responses from internal services, carrier-grade NAT infrastructure, or link-local endpoints that would otherwise be unreachable from external networks. IPv4-mapped IPv6 forms (e.g., [::ffff:0.0.0.0]) also bypassed the existing checks. The security impact is primarily confidentiality: an attacker can read data served by internal services reachable from the MISP server. The MISP instance itself is not compromised, but it is abused as a proxy to access otherwise restricted network resources.
A weakness has been identified in H3C Magic NX15 V100R017. This affects the function importprofile of the file /api/upload. This manipulation of the argument fileName causes path traversal. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. The vendor was contacted early about this disclosure.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.